NCT05594914View on ClinicalTrials.gov

AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

AK104

AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.

All Listed Sponsors
lead

The First Affiliated Hospital of University of South China

OTHER